Anti-Osteoporosis And Fracture Healing Market : Moving Towards a Glaring Growth Rate And Challenges 2028 | Radius Health Inc., Pfizer Inc., Amgen Inc., Novartis AG

Osteoporosis is a condition in which the rate of regeneration of bone tissue is much lower than its rate of disintegration, which causes the bones to become porous. Osteoporosis is more common in women, with a decrease in estrogenic hormone levels leading to more cases after menopause. In osteoporosis, bone strength and structure are affected, increasing the likelihood of fractures, especially in the hip region, wrist, and spine. X-ray-based scanning method, dual energy X-ray absorption (DEXA) or bone density, is used to diagnose the condition. Although there are no obvious symptoms of osteoporosis, it is characterized by weakening of the spine and joint pain.

Request Here For PDF Brochure With Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/2525

Global Anti-Osteoporosis and Fracture Healing Market: Drivers

Recently, new drugs for the treatment of osteoporosis have been approved by various regulatory bodies, such as the European Medicines Agency (EMA), the US Food and Drug Administration (FDA), Medicines and Healthcare Products Regulatory Agency (MHRA) and others. With the approval and launch of such new drugs, the global anti-osteoporosis and fracture healing market is likely to grow in the estimated period. For example, Radius Health Inc., a biopharmaceutical company, was approved by the US Food and Drug Administration (FDA) in April 2017, for the treatment of postmenopausal women with osteoporosis with a high risk of fractures, for TYMLOS (abaloparatide) injection. This drug reduces the incidence of spinal and peripheral skeletal fractures in postmenopausal women.

Moreover, major players are launching new treatment methods for osteoporosis in the market. For example, Ahn-Gook Pharmaceutical Co., Ltd., a South Korean-based pharmaceutical company, received approval from the Korean Ministry of Food and Drug Safety (MFDS) in January 2016, to market Binosto Bufferd alendronate in Korea. Alendronate reduces bone loss and buffering reduces the contact of acidified alendronate in the stomach and oesophagus. The launch of such new products is likely to boost the growth of the global anti-osteoporosis and fracture healing market in the foreseeable future.

Global Anti-Osteoporosis and Fracture Healing Market: Regional Analysis

The launch of new products is likely to significantly increase the growth in the anti-osteoporosis and fracture healing market in North America within estimated period. For example, Zydus Pharma Inc. received approval from the US Food and Drug Administration (FDA) in September 2018, to launch Risedronate Sodium delayed-release tablet in the United States, a drug used to treat osteoporosis in postmenopausal women.

Amgen Inc., an American biopharmaceutical company, received approval from the European Medicines Agency (EMA) Committee on Medicinal Products for Human Use (CHMP) in April 2018 for the marketing of Prolia (Denosumab) in Europe. Denosumab is used to treat bone loss associated with long-term systemic glucocorticoid therapy in patients with increased risk of fracture. This is likely to boost the growth of the European anti-osteoporosis and fracture healing market over the estimated period.

Get Sample Report With Latest Covid19 Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/2525

Amgen Inc and UCB SA announced approval from the Japanese Ministry of Health, Labor and Welfare in January 2018, for the marketing of the drug (Romosozumab) in Japan. Equity is a bone-building agent that plays a dual role in increasing bone formation and reducing bone resorption, thereby reducing the risk of fractures. These factors are likely to support global anti-osteoporosis and fracture healing market growth over the estimated period.

Global Anti-Osteoporosis and Fracture Healing Market: Restraints

Bisphosphonate tablets commonly used for osteoporosis are not well absorbed in the stomach and are involved in side effects such as abdominal pain and heartburn. In addition, in the case of osteoporosis, especially in women, increased awareness of the intake of calcium and vitamin-rich diet and the adoption of physiotherapeutic measures to prevent the occurrence of osteoporosis. These factors are likely to curb global anti-osteoporosis and fracture healing market growth over the estimated period.

Global Anti-Osteoporosis and Fracture Healing Market: Segmentation

On the basis of Drug Class, the Global Anti-Osteoporosis and Fracture Healing Market is segmented into:

• Anabolic Agents

• Teriparatide (Forteo)
• Alendronate (Fosamax)

• Monoclonal Antibodies

• Romosozumab (Evenity)
• Denosumab (Prolia)

• Hormone Replacement Therapy

• Progestin
• Oestrogen
• Others

• Bisphosphonates

• Zoledronic Acid (Reclast)
• Ibandronate (Boniva)
• Risedronate (Actonel)
• Alendronate (Fosamax)

• Others

On the basis of Route of Administration, the Global Anti-Osteoporosis and Fracture Healing Market is segmented into:

• Injection
• Oral

On the basis of Distribution Channel, the Global Anti-Osteoporosis and Fracture Healing Market is segmented into:

• Online Pharmacies
• Retail Pharmacies
• Hospital Pharmacies

On the basis of Region, the Global Anti-Osteoporosis and Fracture Healing Market is segmented into:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

Global Anti-Osteoporosis and Fracture Healing Market: Competitive Landscape

Key players performing in the global anti-osteoporosis and fracture healing market are PhytoHealth Corporation, Lilly and Company Limited, Eli, F. Hoffman-La Roche AG, Inc., Merck & Co., GlaxoSmithKline Plc., Novartis AG, Amgen Inc., Pfizer Inc., and Radius Health Inc.

Buy This Complete Business Report With Flat USD 2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/2525

Reasons to Purchase This Report

• Current and future of Anti-Osteoporosis And Fracture Healing Market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players

Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Anti-Osteoporosis And Fracture Healing Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Anti-Osteoporosis And Fracture Healing Industry Impact

Chapter 2 Global Anti-Osteoporosis And Fracture Healing Competition by Types, Applications, and Top Regions and Countries
2.1 Global Anti-Osteoporosis And Fracture Healing (Volume and Value) by Type
2.3 Global Anti-Osteoporosis And Fracture Healing (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Anti-Osteoporosis And Fracture Healing Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Anti-Osteoporosis And Fracture Healing Market Analysis
Chapter 6 East Asia Anti-Osteoporosis And Fracture Healing Market Analysis
Chapter 7 Europe Anti-Osteoporosis And Fracture Healing Market Analysis
Chapter 8 South Asia Anti-Osteoporosis And Fracture Healing Market Analysis
Chapter 9 Southeast Asia Anti-Osteoporosis And Fracture Healing Market Analysis
Chapter 10 Middle East Anti-Osteoporosis And Fracture Healing Market Analysis
Chapter 11 Africa Anti-Osteoporosis And Fracture Healing Market Analysis
Chapter 12 Oceania Anti-Osteoporosis And Fracture Healing Market Analysis
Chapter 13 South America Anti-Osteoporosis And Fracture Healing Market Analysis
Chapter 14 Company Profiles and Key Figures in Anti-Osteoporosis And Fracture Healing Business
Chapter 15 Global Anti-Osteoporosis And Fracture Healing Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology